Esperion Therapeutics (ESPR) Tops Q2 EPS by 12c
Tweet
Share
E-mail
Get Alerts ESPR Hot Sheet
Join SI Premium – FREE
Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $82.39 million versus the consensus estimate of $63.54 million.
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Starts TIME dotCom Berhad (TDC:MK) at Overweight
- Goldman Sachs Reiterates Buy Rating on NetEase.com (NTES)
- JPMorgan Downgrades Astral Ltd (ASTRA:IN) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
